Search

Clascoterone

[L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766] … [A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older.

Sertaconazole

It is available in topical formulations for the treatment of skin infections such as athlete's foot.

Nitazoxanide

Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

Baricitinib

[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … the use of baricitinib for the treatment of COVID-19 in May 2022.

Sodium ascorbate

Sotatercept

[L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

Luliconazole

Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand nam...

Ferumoxytol

[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.

Sofosbuvir

NS5B, an RNA-dependent RNA polymerase, is essential for the transcription of Hepatitis C viral RNA and for its high replicative rate and genetic diversity [A19594]. … in combination with other antivirals for all six genotypes of Hepatitis C [L852].

Ensitrelvir

Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).